Holoprosencephaly (HPE), a common developmental forebrain malformation, is characterized by failure of the cerebrum to completely divide into left and right hemispheres. The etiology of HPE is heterogeneous and a number of environmental and genetic factors have been identified. Cytogenetically visible alterations occur in 25% to 45% of HPE patients and cytogenetic techniques have long been used to study copy number variants (CNVs) in this disorder. The karyotype approach initially demonstrated several recurrent chromosomal anomalies, which led to the identification of HPEspecific loci and, eventually, several major HPE genes. More recently, higher-resolution cytogenetic techniques such as subtelomeric multiplex ligation-dependent probe amplification and chromosomal microarray have been used to analyze chromosomal anomalies. By using chromosomal microarray, we sought to identify submicroscopic chromosomal deletions and duplications in patients with HPE.
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In an analysis of 222 individuals with HPE, a deletion or duplication was detected in 107 individuals.
Of these 107 individuals, 23 (21%) had variants that were classified as pathogenic or likely pathogenic by board-certified medical geneticists. We identified multiple patients with deletions in established HPE loci as well as three patients with deletions encompassed by 6q12-q14.3, a CNV previously reported by Bendavid et al. In addition, we identified a new locus, 16p13.2 that warrants further investigation for HPE association. Incidentally, we also found a case of Potocki-Lupski syndrome, a case of Phelan-McDermid syndrome, and multiple cases of 22q11.2 deletion syndrome within our cohort. These data confirm the genetically heterogeneous nature of HPE, and also demonstrate clinical utility of chromosomal microarray in diagnosing patients affected by HPE.
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| I N TR ODU C TI ON
Holoprosencephaly (HPE) is the most common congenital anomaly of the developing forebrain in humans, occurring in approximately 1:250 conceptuses (Matsunaga & Shiota, 1977) . HPE is characterized by failure of the cerebrum to form fully distinct right and left hemispheres, resulting in partial or complete fusion of the cerebral cortex and underlying structures across the midline. Classic HPE can present with cognitive impairments, seizures, and distinct craniofacial abnormalities such as cyclopia (one eye), synophthalmia (two fused eyes), and proboscis.
Less severe forms of HPE, often referred to as microform HPE, may present with no cognitive impairment and milder craniofacial abnormalities such as microcephaly, hypotelorism, cleft lip and/or palate, and a single maxillary central incisor (Muenke & Beachy, 2001; Solomon et al., 2010) .
HPE is etiologically heterogeneous, and a number of both environmental and genetic causes have been identified Muenke & Beachy, 2000) . Familial inheritance of HPE can occur as a part of multiple-malformation syndromes, inherited in either an autosomal dominant or autosomal recessive manner, such as SmithLemli-Opitz syndrome (reviewed in this issue; Kruszka & Muenke, 2018) , or can be inherited in an isolated manner (Kruszka, Hart, Hadley, Muenke, & Habal, 2015; Stokes et al., 2018) . Furthermore, cytogenetic anomalies, such as trisomy 13 and trisomy 18, can cause HPE (Kruszka & Muenke, 2018; Roessler & Muenke, 1998) . In general, cytogenetic anomalies are estimated to be present in 25% to 45% of individuals with HPE (Bullen, Rankin, & Robson, 2001; Croen, Shaw, & Lammer, 1996; Olsen, Hughes, Youngblood, & Sharpe-Stimac, 1997 ).
Analysis of cytogenetic anomalies has long been used in the diagnosis and study of HPE. An association between SIX3 and HPE was first suggested by our group (M€ uenke et al., 1988) after a deletion in 2p21 in a patient with HPE was identified through high-resolution analysis of GTG-banded chromosomes. At the time, we also began to recognize specific patterns of chromosomal anomalies associated with HPE ( Figure 1 ; M€ unke, Emanuel, & Zackai, 1988) . Detection of recurrent chromosomal anomalies by karyotype eventually led to the identification of 12 HPE candidate loci (Roessler et al., 1998) . Molecular studies of these regions helped identify four major causative genes in HPE, including SHH at 7q36 (OMIM 600725) (Belloni et al., 1996; Roessler et al., 1996) , ZIC2 at 13q32 (OMIM 603073) (Brown et al., 1998) , TGIF1 at 18p11.3 (OMIM 602630) (Gripp et al., 2000) , and SIX3 at 2p21 (OMIM 603714) (Wallis et al., 1999) .
Sequence variants in these four major genes, however, only account for approximately 25% of genetic cases of HPE after excluding for chromosomal anomalies (Dubourg et al., 2007) . Further studies on chromosomal anomalies helped reveal more candidate HPE loci ( Figure 2 ) and led to the establishment of the SHH signaling pathway as a hallmark in HPE pathogenicity: PTCH1 at 9q22 (OMIM 601309) , GLI2 at 2q14 (OMIM 165230) (Roessler et al., 2003) , and DISP1 at 1q41 (OMIM 607502) (Roessler & Muenke, 2009) . Coinciding with these discoveries was the identification of two contributory genes in the NODAL/TGF-b pathway: TDGF1 at 3p21.31 (OMIM 187395) (de la Cruz et al., 2002) and FOXH1 at 8q24.3 (OMIM 603621) (Roessler et al., 2008) .
With the advent of technologies such as subtelomeric multiplex ligation-dependent probe amplification (MLPA), which is capable of greater resolution than traditional karyotype analysis (Schouten et al., 2002) , groups such as Bendavid et al. (2007) were able to identify candidate HPE loci in novel subtelomeric regions not previously reported FIG URE 1 Correlation between chromosome abnormalities and the holoprosencephaly spectrum. Hatched bars on the left side of chromosomes represent deletions, full bars on the right, duplications. Thin bars indicate individual case reports, whereas thick bars represent more than three reports. Ring chromosomes are represented by hatched bars on the terminal ends (M€ unke et al., 1988) FIGURE 2 Chromosomal anomalies in holoprosencephaly. At least 12 human chromosomal regions have been implicated in the pathogenesis of holoprosencephaly on the basis of structural anomalies. With the exception of one region on 3p, which is duplicated, all other chromosomal regions shown here are deleted in holoprosencephaly. At the time of publication, four genes had been identified by positional candidate gene approach and two, dispatched (DISP) and HNF3b, had been proposed as additional holoprosencephaly genes (modified from by karyotype analysis. Bendavid et al. (2007) screened 181 patients with HPE using MLPA and found six patients with chromosomal anomalies in novel regions, including two cases each with a 1p deletion, and one each with a 5q deletion associated with a 17q gain, an 18q deletion associated with a Xq gain, a 15q subcentromeric gain, and a 22q deletion, respectively. However, subtelomeric MLPA has important limitations, such as the extrapolation of copy-number alterations of a relatively small probe to a rather large subtelomeric region. As consequence, these CNVs detected by this MLPA assay may not represent the minimal critical region for such subtelomeric disorders. To date, no novel HPE genes have been identified in these regions. patients with de novo gains and/or losses, some of whom had deletions in previously identified HPE loci, such as 21q22.3 (HPE1) and 14q13 (HPE8). However, they also identified deletions in new candidate loci not previously associated with HPE, including one patient with a deletion including 1p31.3-p31.1, one with a 6q12-q14.3 deletion, four patients with a 10p12.1 deletion, one with a 19pter deletion, and one with a Xp11.23-p11.22 deletion. Given the lack of follow-up studies on these rather large regions and the complex genetic heterogeneity of HPE, further investigation of these loci is required to determine their clinical significance. In this study, we evaluated 222 patients with HPE for copy number variants (CNVs) using array CGH to potentially corroborate past findings by other groups and identify new HPE loci.
| M A TE RI A L S A ND M E TH ODS

| Patients
We studied 222 pediatric and adult patients with HPE spectrum ascertained through our institutional review board approved research 
| Chromosomal microarrays
Patients were screened for CNVs through one of three different CMA designs. Patients were recruited at various points over the span of a few years. Assignment of a patient to a given CMA design was dependent on the time of recruitment and available technology, as opposed to his or her specific phenotype or previous test results.
Group 1, which only consists of two patients, was evaluated with CMA as previously described (Stokes et al., 2018) . Group 2 was screened using SurePrint G3 Custom Microarrays with 180K probes distributed throughout the genome, with denser coverage over regions of clinical interest and chromosome X (Agilent Technologies, Inc.). It should be noted that, within this group of patients, eight patients with known deletions in 18p were intentionally included. 
| Interpretation of CNVs
The CNVs generated for all groups were evaluated for clinical relevance by a board-certified medical geneticists (D.E.P., J.E.M., P.K.) according to the standards and guidelines established by the American College of Medical Genetics (Kearney et al., 2011; South et al., 2013) and the framework for assessing dosage sensitivity established by the International Standards for Cytogenomic Arrays Consortium (Riggs et al., 2012) .
| RE S U L TS
We screened 222 patients with HPE and identified CNVs in 107 individuals (48%) ranging in size from 2 kb to 58 Mb (Supporting Information Tables I and II) . However, a large portion of these variants are likely benign, or are variants of unknown significance (VUS). Out of the 107 patients who had clinically significant CNVs, only 23 patients (21%) had variants that would be reported as pathogenic or likely pathogenic in a clinical setting ( Table 2) . As expected, 18 these patients exhibited deletions in well-established HPE loci, including three cases with a deletion including SIX3, one case with a deletion including SHH, 11 cases with a deletion in TGIF1 (8 of which were previously identified and intentionally included in our study as positive controls), one case with a deletion in ZIC2, one case with a deletion in GLI2, and one case with a deletion in DISP1. Also of note, three patients exhibited deletions encompassed by a deletion found earlier by Bendavid et al. (2009), 6q12-q14.3 . In addition to these findings, we discovered a deletion in 16p13.2, a region that we believe warrants further investigation.
| D I SCUSSION
We examined 222 individuals within the HPE spectrum using CMA.
CNVs were found in six established HPE loci, including SIX3 (3), SHH
(1), TGIF1 (11), ZIC2 (1), GLI2 (1), and DISP1 (1). Two of the patients with deletions encompassing SIX3 (Stokes et al., 2018) and eight of the patients with deletions encompassing TGIF1 (Kauvar et al., 2011) have previously been reported. The two patients with deletions in SIX3 were recruited to our study before the deletions were discovered. However, the eight patients with deletions in TGIF1 reported by Kauvar et al. (2011) had known deletions in 18p when they were recruited. These patients were included in the present study to ascertain the specific breakpoints in their deletions and to determine whether their deletions encompassed TWSG1, which, at the time, was considered a candidate HPE gene. As Kauvar et al. (2011) later concluded, however, sequence alterations in TWSG1 are not a common direct cause for HPE.
While the inclusion of these eight patients skews our results by increasing the percentage of patients with pathogenic or likely pathogenic deletions from 14% (15/107) to 21% (23/107) and artificially inflates the incidence of TGIF1 deletions within our study population, loss of function variants in TGIF1, as well as in SHH, ZIC2, and SIX3, are, nevertheless, widely recognized causes of HPE (reviewed in this issue
in Roessler et al., 2018 ) and our present study supports this. There is less data, however, to support the association between HPE and deletions in GLI2 and DISP1. Rather, there has been increasing evidence that variants in GLI2 lead to a set of phenotypes, predominated by pituitary anomalies, polydactyly, and subtle facial features, separate from HPE (Bear et al., 2014; Kruszka & Muenke, 2018) . Similarly, a study by Jun et al. (2013) , characterized a patient with a 183 kb deletion encompassing DISP1 that presented with no midline defects, brain abnormalities, or facial dysmorphism, which calls into question the role of DISP1 as a causative gene in HPE. Our results seem to support the association between GLI2 and DISP1 and HPE; however, it should also be taken into consideration that the patients with deletions in GLI2 and DISP1 in our cohort were reported as having HPE findings, but due to lack of follow-up we were unable to determine the specific HPE type and phenotypic presentation.
Our cohort also contained three individuals with similar deletions to one reported by Bendavid et al., 6q12q14.3(69,637,936-86,100,038)x1). The 16.9 Mb deletion reported by Bendavid et al. (2009) encompasses the three we discovered in our cohort which included only part of 6q13 or 6q13-q14.1 and were all less than 2 Mb in size. Deletions in the proximal region of 6q have been associated with a phenotypic spectrum, including intellectual disability, upslanted palpebral fissures with epicanthal folds, a short nose with broad nasal tip, anteverted nares, long philtrum, and thin upper lip, that closely overlaps with the HPE spectrum (Becker et al., 2012) .
Catena, Aracena, Pizarro, Espinoza, and Lay-Son, (2017), however, have suggested that deletions in this region could be related Toriello-Carey syndrome, key features of which includes postnatal growth failure, hypotonia, developmental delay, a short neck, characteristic facial anomalies such as hypertelorism, blepharophimosis, abnormal ears, small nose, full cheeks, thin lips, micrognathia, and abnormal corpus callosum (Toriello et al., 2003) . Unfortunately, the patient presented by Bendavid et al. (2009) was only described as having "minor signs" of HPE and the patients with proximal 6q deletions in our cohort exhibited microform HPE or "HPE findings," which makes it more difficult to evaluate the possibility that these patients were misdiagnosed. Regardless of the syndromic diagnosis, little correlation has been found between specific genes in the proximal 6q region and the phenotypes mentioned thus far.
In addition to the aforementioned CNVs, we identified a new locus of interest within our cohort. We observed one case with a deletion in 16p13.2 encompassing GRIN2A (OMIM 138253). Interestingly, this patient also has a deletion in 6q13, which we do not believe contributes to his phenotypic presentation. A study by Reutlinger et al. (2010) presented patients with deletions spanning GRIN2A who had choanal stenosis, intellectual disability, and seizures. Although GRIN2A is primarily associated with epilepsy, the patients presented by Reutlinger While CMA continues to be a powerful tool in the study and diagnosis of fetal anomalies (South et al., 2013) , advances in nextgeneration sequencing (NGS) technology has led to its increased use in the discovery of both sequence variants and CNVs that underlie phenotype and disease. The NGS approach allows for higher coverage and resolution, more accurate estimation of copy numbers, and higher capability of identifying novel CNVs (Alkan, Coe, & Eichler, 2011; Meyerson, Gabriel, & Getz, 2010) . Several groups such as Dubourg et al. (2016) have already begun using NGS to detect sequence variants in HPE and, as a result, were able to determine the frequency at which variants in genes in the fibroblast growth factor family occur in HPE, confirming previous work by group such as ours (Arauz et al., 2010) .
In summary, we screened 222 patients with HPE with CMA and found 23 (10%) individuals to have pathogenic or likely pathogenic variants, supporting the importance of CMA in the workup of HPE. We also provide a large database of CNVs (Supporting Information Tables I   and II) in individuals with HPE that will be used as a reference by clinicians and laboratories for years to come. As sequencing technology improves, especially with CNV calls being made from NGS, we expect continued refinement of CNVs in HPE.
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